International immunopharmacology · 2026
Salvianolic acid B increases the stability of atherosclerotic vulnerable plaques by inhibiting macrophage apoptosis via the Piezo1/JNK pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zou Lisi, Meng Peina, Li Zongli, Ou Xinyan, Guo Xiran, Zhang Qihui, Xu Yaxin, Wang Jianmei, Sun Xuyan, Liu Qingyin, Fang Yuan, Xu Xiaojin, Pei Ke
Аннотация
BACKGROUND: Atherosclerosis is the leading cause of cardiovascular morbidity and mortality, and plaque vulnerability is a critical determinant of acute cardiovascular events. Previous studies have reported that Salvianolic acid B (Sal-B), a main active constituent of Salvia miltiorrhiza, inhibits AS by targeting Piezo1 and have clarified its anti-inflammatory and antioxidant effects in endothelial cells. However, the specific signaling pathway downstream of Piezo1 that regulates apoptosis in macrophages remains unclear, and the molecular mechanism by which Sal-B affects macrophage apoptosis through directly regulating Piezo1 still needs to be further explored.
OBJECTIVE: This study aimed to investigate the protective effects of Sal-B on atherosclerosis and to elucidate the underlying molecular mechanisms, with particular emphasis on macrophage apoptosis and the Piezo1-JNK signaling pathway.
METHODS: An atherosclerosis model was established in ApoE-/- mice fed a high-fat diet, followed by oral administration of Sal-B at different doses. Plaque morphology, fibrous cap thickness, and lipid profiles were assessed using Oil Red O, hematoxylin and eosin (H&E), and Masson's staining. Macrophage apoptosis and related protein expression were evaluated by TUNEL staining, flow cytometry, Western blotting, and immunohistochemistry in both in vivo and in vitro experiments.
RESULTS: Sal-B significantly reduced plaque area, increased fibrous cap thickness, and improved serum lipid profiles. It markedly downregulated the expression of pro-apoptotic Bax and cleaved caspase-3 while upregulating the anti-apoptotic protein Bcl-2, thereby inhibiting macrophage apoptosis. Consistently, Sal-B suppressed the expression of Piezo1, JNK, and phosphorylated JNK (p-JNK) in vivo and in vitro. Overexpression of Piezo1 enhanced JNK/p-JNK activation, increased Bax and cleaved caspase-3 levels, decreased Bcl-2 expression, and aggravated macrophage apoptosis, indicating that excessive Piezo1 activity may counteract the anti-apoptotic effects of Sal-B.
CONCLUSION: Sal-B stabilizes atherosclerotic plaques by suppressing Piezo1 activation and downstream JNK/p-JNK signaling, thereby reducing macrophage apoptosis, limiting necrotic core expansion, and ultimately attenuating the progression of atherosclerosis. This finding offers novel mechanistic insights into the anti-atherosclerotic effects of Sal-B and identifies the macrophage apoptosis-related Piezo1 channel as a potential therapeutic target for atherosclerotic lesions.
OBJECTIVE: This study aimed to investigate the protective effects of Sal-B on atherosclerosis and to elucidate the underlying molecular mechanisms, with particular emphasis on macrophage apoptosis and the Piezo1-JNK signaling pathway.
METHODS: An atherosclerosis model was established in ApoE-/- mice fed a high-fat diet, followed by oral administration of Sal-B at different doses. Plaque morphology, fibrous cap thickness, and lipid profiles were assessed using Oil Red O, hematoxylin and eosin (H&E), and Masson's staining. Macrophage apoptosis and related protein expression were evaluated by TUNEL staining, flow cytometry, Western blotting, and immunohistochemistry in both in vivo and in vitro experiments.
RESULTS: Sal-B significantly reduced plaque area, increased fibrous cap thickness, and improved serum lipid profiles. It markedly downregulated the expression of pro-apoptotic Bax and cleaved caspase-3 while upregulating the anti-apoptotic protein Bcl-2, thereby inhibiting macrophage apoptosis. Consistently, Sal-B suppressed the expression of Piezo1, JNK, and phosphorylated JNK (p-JNK) in vivo and in vitro. Overexpression of Piezo1 enhanced JNK/p-JNK activation, increased Bax and cleaved caspase-3 levels, decreased Bcl-2 expression, and aggravated macrophage apoptosis, indicating that excessive Piezo1 activity may counteract the anti-apoptotic effects of Sal-B.
CONCLUSION: Sal-B stabilizes atherosclerotic plaques by suppressing Piezo1 activation and downstream JNK/p-JNK signaling, thereby reducing macrophage apoptosis, limiting necrotic core expansion, and ultimately attenuating the progression of atherosclerosis. This finding offers novel mechanistic insights into the anti-atherosclerotic effects of Sal-B and identifies the macrophage apoptosis-related Piezo1 channel as a potential therapeutic target for atherosclerotic lesions.